[Short version of the S2k guideline on drug therapy of neurogenic lower urinary tract dysfunction (NLUTD)].
Kurzfassung der S2k-Leitlinie medikamentöse Therapie der neurogenen Dysfunktion des unteren Harntraktes (NLUTD).
Antimuscarinic therapy
Botulinum neurotoxins
Detrusor sphincter dyssynergia
Neurogenic detrusor overactivity
Neurogenic detrusor underactivity
Journal
Urologie (Heidelberg, Germany)
ISSN: 2731-7072
Titre abrégé: Urologie
Pays: Germany
ID NLM: 9918384886606676
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
accepted:
12
09
2022
pubmed:
22
10
2022
medline:
25
1
2023
entrez:
21
10
2022
Statut:
ppublish
Résumé
In Germany about one million patients suffer from neurogenic lower urinary tract dysfunction (NLUTD). If left untreated, various forms of NLUTD can lead to secondary damage of the lower and upper urinary tract. Thus, the guideline was developed for the drug therapy of patients with NLUTD, who frequently require lifelong care and aftercare. The guideline was developed in a consensus process with several meetings and online reviews, and final recommendations were decided on in online consensus meetings. Ballots were sent to elected officials of the contributing professional societies. Level of consensus was given for each coordinated recommendation ( https://www.awmf.org/leitlinien/detail/ll/043-053.html ). RESULTS/MOST IMPORTANT RECOMMENDATIONS: (Video)urodynamic classification of the NLUTD should be conducted before the use of antimuscarinic drugs (84.2%). Approved oral antimuscarinics should be used as first choice. Contraindications must be respected (100%). If oral treatment is ineffective or in the case of adverse drug reaction (ADRs) alternatively instillation of oxybutynin solution intravesically (83%) or onabotulinumneurotoxine (OBoNT) injection should be offered (89.5%). In case of failure or ADRs of antimuscarinics, β3 sympathomimetic mirabegron can be used to treat neurogenic detrusor overactivity (NDO) (off-label use) (100%). In case of paraplegia below C8 or multiple sclerosis with an expanded disability status scale (EDSS) of ≤ 6.5, OBoNT injection can be offered as an alternative (89.5%). Drug therapy for NDO should be started early in newborns/young children (84.2%). Conservative, nondrug therapy should be considered in frail elderly (94.7%). No parasympathomimetic therapy should be used to treat neurogenic detrusor underactivity (94.7%). Precise knowledge of the neurological underlying disease/sequence of trauma and the exact classification of the NLUTD are required for development of individualized therapy. PROBLEMSTELLUNG: Etwa 1 Mio. Patienten leiden in Deutschland an einer neurogenen Dysfunktion des unteren Harntraktes („neurogenic lower urinary tract dysfunction“, NLUTD). Unbehandelt können verschiedene Formen der NLUTD zu sekundären Schädigungen am unteren (UHT) und oberen Harntrakt (OHT) führen. Die Leitlinie wurde für die medikamentöse Therapie von Patienten mit NLUTD entwickelt, die häufig einer lebenslangen Therapie und Nachsorge bedürfen. Die Leitlinie wurde in einem Konsensusverfahren mit mehreren Treffen und Online-Reviews entwickelt. Finale Empfehlungen wurden in Online-Konferenzen und mittels Stimmzettel mit allen beteiligten Fachgesellschaften ermittelt. Für jede eingehend diskutierte Empfehlung wurde der Grad des Konsensus angegeben. Die (video)urodynamische Klassifikation der NLUTD sollte vor Beginn einer antimuskarinergen Therapie durchführt werden (84,2 %). Zugelassene orale Antimuskarinika sollten bei neurogener Detrusorüberaktivität (NDO) als erste Wahl eingesetzt werden. Kontraindikationen müssen beachtet werden (100 %). Im Falle von UAW oder bei ineffektiver oraler Medikation sollten alternativ die Instillation von Oxybutynin-Lösung in die Harnblase (83 %) oder die Onabotulinumneurotoxin (OBoNT)-Injektion angeboten werden (89,5 %). Im Falle des Versagens der antimuskarinergen Therapie (AMT) oder bei unerwünschten Arzneimittelwirkungen (UAW) können das β Die genaue Kenntnis der zugrunde liegenden neurologischen Erkrankung/Traumafolge und die exakte Klassifikation der NLUTD sind Voraussetzung für die Entwicklung einer individuell abgestimmten Therapie.
Sections du résumé
BACKGROUND
BACKGROUND
In Germany about one million patients suffer from neurogenic lower urinary tract dysfunction (NLUTD). If left untreated, various forms of NLUTD can lead to secondary damage of the lower and upper urinary tract. Thus, the guideline was developed for the drug therapy of patients with NLUTD, who frequently require lifelong care and aftercare.
METHODS
METHODS
The guideline was developed in a consensus process with several meetings and online reviews, and final recommendations were decided on in online consensus meetings. Ballots were sent to elected officials of the contributing professional societies. Level of consensus was given for each coordinated recommendation ( https://www.awmf.org/leitlinien/detail/ll/043-053.html ). RESULTS/MOST IMPORTANT RECOMMENDATIONS: (Video)urodynamic classification of the NLUTD should be conducted before the use of antimuscarinic drugs (84.2%). Approved oral antimuscarinics should be used as first choice. Contraindications must be respected (100%). If oral treatment is ineffective or in the case of adverse drug reaction (ADRs) alternatively instillation of oxybutynin solution intravesically (83%) or onabotulinumneurotoxine (OBoNT) injection should be offered (89.5%). In case of failure or ADRs of antimuscarinics, β3 sympathomimetic mirabegron can be used to treat neurogenic detrusor overactivity (NDO) (off-label use) (100%). In case of paraplegia below C8 or multiple sclerosis with an expanded disability status scale (EDSS) of ≤ 6.5, OBoNT injection can be offered as an alternative (89.5%). Drug therapy for NDO should be started early in newborns/young children (84.2%). Conservative, nondrug therapy should be considered in frail elderly (94.7%). No parasympathomimetic therapy should be used to treat neurogenic detrusor underactivity (94.7%).
CONCLUSION
CONCLUSIONS
Precise knowledge of the neurological underlying disease/sequence of trauma and the exact classification of the NLUTD are required for development of individualized therapy.
ZUSAMMENFASSUNG
UNASSIGNED
PROBLEMSTELLUNG: Etwa 1 Mio. Patienten leiden in Deutschland an einer neurogenen Dysfunktion des unteren Harntraktes („neurogenic lower urinary tract dysfunction“, NLUTD). Unbehandelt können verschiedene Formen der NLUTD zu sekundären Schädigungen am unteren (UHT) und oberen Harntrakt (OHT) führen. Die Leitlinie wurde für die medikamentöse Therapie von Patienten mit NLUTD entwickelt, die häufig einer lebenslangen Therapie und Nachsorge bedürfen.
METHODEN
METHODS
Die Leitlinie wurde in einem Konsensusverfahren mit mehreren Treffen und Online-Reviews entwickelt. Finale Empfehlungen wurden in Online-Konferenzen und mittels Stimmzettel mit allen beteiligten Fachgesellschaften ermittelt. Für jede eingehend diskutierte Empfehlung wurde der Grad des Konsensus angegeben.
ERGEBNISSE/EMPFEHLUNGEN
UNASSIGNED
Die (video)urodynamische Klassifikation der NLUTD sollte vor Beginn einer antimuskarinergen Therapie durchführt werden (84,2 %). Zugelassene orale Antimuskarinika sollten bei neurogener Detrusorüberaktivität (NDO) als erste Wahl eingesetzt werden. Kontraindikationen müssen beachtet werden (100 %). Im Falle von UAW oder bei ineffektiver oraler Medikation sollten alternativ die Instillation von Oxybutynin-Lösung in die Harnblase (83 %) oder die Onabotulinumneurotoxin (OBoNT)-Injektion angeboten werden (89,5 %). Im Falle des Versagens der antimuskarinergen Therapie (AMT) oder bei unerwünschten Arzneimittelwirkungen (UAW) können das β
SCHLUSSFOLGERUNG
UNASSIGNED
Die genaue Kenntnis der zugrunde liegenden neurologischen Erkrankung/Traumafolge und die exakte Klassifikation der NLUTD sind Voraussetzung für die Entwicklung einer individuell abgestimmten Therapie.
Autres résumés
Type: Publisher
(ger)
PROBLEMSTELLUNG: Etwa 1 Mio. Patienten leiden in Deutschland an einer neurogenen Dysfunktion des unteren Harntraktes („neurogenic lower urinary tract dysfunction“, NLUTD). Unbehandelt können verschiedene Formen der NLUTD zu sekundären Schädigungen am unteren (UHT) und oberen Harntrakt (OHT) führen. Die Leitlinie wurde für die medikamentöse Therapie von Patienten mit NLUTD entwickelt, die häufig einer lebenslangen Therapie und Nachsorge bedürfen.
Identifiants
pubmed: 36271186
doi: 10.1007/s00120-022-01950-0
pii: 10.1007/s00120-022-01950-0
doi:
Substances chimiques
Muscarinic Antagonists
0
Types de publication
English Abstract
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
41-52Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
Références
Abrams P, Amarenco G, Bakke A et al (2003) Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. J Urol 170:1242–1251
doi: 10.1097/01.ju.0000084623.65480.f8
Abrams P, Kelleher C, Staskin D et al (2015) Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB): safety results from a phase 2 study (symphony). Eur Urol 67:577–588
doi: 10.1016/j.eururo.2014.02.012
Alsulihem A, Corcos J (2019) Evaluation, treatment, and surveillance of neurogenic detrusor overactivity in spinal cord injury patients. Neuroimmunol Neuroinflamm 6:13
Amarenco G, Sutory M, Zachoval R et al (2017) Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivty: results from the doble-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourol Urodyn 36:414–421
doi: 10.1002/nau.22945
Amend B, Hennenlotter J, Schäfer T et al (2008) Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol 53:1021–1028
doi: 10.1016/j.eururo.2008.01.007
Andersson KE, Appell RA, Cardozo LD et al (1999) The pharmacological treatment of urinary incontinence. BJU Int 84:923–947
doi: 10.1046/j.1464-410x.1999.00397.x
Andersson KE, Chapple CR, Cardozo L et al (2012) Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A (Hrsg) Incontinence 5th International Consultation on Incontinence. EAU—ICUD, Paris, S 662–663
Andersson KE, Chapple CR, Cardozo L et al (2012) Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A (Hrsg) Incontinence 5th Internatinal Consultation on Incontinence. EAU—ICUD, Paris, S 693
Apostolidis A, Drake MJ, Emmanuel A et al (2017) Neurologic urinary and feacal incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A (Hrsg) Incontinence 6th International Consultation on Incontinence, Tokyo, S 1093–1280
Athanasopoulos A (2011) The pharmacotherapy of overactive bladder. Expert Opin Pharmacother 12:1003–1005
doi: 10.1517/14656566.2011.554397
Averbeck MA (2021) Editorial comment: long-term outcomes and risks factors for failure of intradetrusor onabotulinumtoxin A injections for the treatment of refractory neurogenic detrusor overactivity. Int Braz J Urol 47:454–455
doi: 10.1590/s1677-5538.ibju.2021.02.03
Baldessarini RJ (1998) Medikamente und die Behandlung psychiatrischer Erkrankungen. In: Dominiak P, Harder S, Paul M, Unger T (Hrsg) Pharmakologische Grundlagen der Arzneimitteltherapie. McGraw-Hill, London, New York, S 445–474
Barendrecht MM, Oelke M, Laguna MP et al (2007) Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based? BJU Int 99:749–752
doi: 10.1111/j.1464-410X.2006.06742.x
Bennet N, O’Leary M, Patel AS et al (2004) Can higher doses of oxybutynin improve efficacy in neurogenic bladder. J Urol 171:749–751
doi: 10.1097/01.ju.0000103274.38694.b1
Berges R (2002) Pharmakologische Therapie von prostatabedingten Miktionsstörungen. In: Truss MC, Stief C, Machtens S, Wagner T, Jonas U (Hrsg) Pharmakotherapie in der Urologie. Springer, Berlin, Heidelberg, S 271–275
Böthig R, Domurath B, Bremer J et al (2019) Neuro-urologische Versorgung querschnittgelähmter Patienten. S2k-Leitlinie, AWMF-Register Nr: 179/001. https://www.awmf.org/leitlinien/detail/ll/179-001.html . Zugegriffen: 31. Mai 2022
Böthig R, Kaufmann A, Bremer J et al (2014) Botulinumneurotoxin Typ A bei neurogener Detrusorüberaktivität Konsensus des Arbeitskreises Neuro-Urologie der DMGP. Urologe 53:524–530
doi: 10.1007/s00120-013-3419-7
Buyse G, Waldeck K, Verpoorten C et al (1998) Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J Urol 160:892–896
doi: 10.1016/S0022-5347(01)62828-3
Bycroft J, Leaker B, Wood S et al (2003) The effect of darifenacin on neurogenic detrusor overactivity in patients with spinal cord injury. Neurourol Urodyn 22:A190
Callegari E, Malhotra B, Bungay PJ et al (2011) A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol 72:235–246
doi: 10.1111/j.1365-2125.2011.03961.x
Cameron AP, Clemens JQ, Latini JM et al (2009) Combination drug therapy improves compliance of the neurogenic bladder. J Urol 182:1062–1067
doi: 10.1016/j.juro.2009.05.038
Chancellor M, Boone T (2012) Anticholinergics for overactive bladder therapy: central nervous system effects. CNS Neurosci Ther 18:167–174
doi: 10.1111/j.1755-5949.2011.00248.x
Chapple CR, Yamanishi T, Chess-Williams R (2002) Muscarinic receptor subtypes and mangement of the overactive bladder. Urology 60:82–88
doi: 10.1016/S0090-4295(02)01803-4
Chen SL, Bih LI, Huang YH et al (2008) Effect of single Botulinum toxin A injection to the external urethral sphincter for treating detrusor external sphincter dyssynergia in spinal cord injury. J Rehabil Med 40:744–748
doi: 10.2340/16501977-0255
Cho YS, Kim KH (2016) Botulinum toxin in spinal cord injury patients with neurogenic detrusor overactivity. J Exerc Rehabil 12:624–631
doi: 10.12965/jer.1632874.437
Christoph F, Moschkowitsch A, Kempkensteffen C et al (2007) Long-term efficacy of tolterodine and patient compliance in pediatric patients with neurogenic detrusor overactivity. Urol Int 79:55–59
doi: 10.1159/000102915
Constantini E, Lazzeri M, Bini V et al (2009) Open-label, longitudinal study of tamsulosin for functional bladder outlet obstruction in women. Urol Int 83:311–315
doi: 10.1159/000241674
Cruz F, Herschorn S, Aliotta P et al (2011) Efficacy and safety of onabotulinumtoxin A in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 60:742–750
doi: 10.1016/j.eururo.2011.07.002
De Groat WC (2011) Autonomic regulation of the urinary bladder and urethra. In: Llewellyn-Smith IJ, Ververne AJM (Hrsg) Central regulation of autonomic functions. Oxford University, Oxford, S 345–365
doi: 10.1093/acprof:oso/9780195306637.003.0019
De Groat WC, Yoshimura N (2001) Pharmacology of the lower urinary tract. Annu Rev Pharmacol Toxicol 41:691–721
doi: 10.1146/annurev.pharmtox.41.1.691
De Sèze M, Petit H, Gallien P et al (2002) Botulinum A toxine and detrusor sphincter dyssyergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol 42:56–62
doi: 10.1016/S0302-2838(02)00209-9
De Wachter S, Wyndaele JJ (2003) Intravesical oxybutynin: a local anesthetic effect on bladder afferents. J Urol 169:1892–1895
doi: 10.1097/01.ju.0000049903.60057.4b
Deutsche Gesellschaft für Geriatrie (2022) Was ist Geriatrie? https://www.dggeriatrie.de . Zugegriffen: 15. Aug. 2022
Domurath B, Kutzenberger J (2011) Langzeitergebnisse der Anwendung von Botulinumneurotoxin (BoNT) zur Behandlung einer neurogenen OAB bei querschnittgelähmten Patienten. Abstracts des 63. Kongresses der DGU. Urologie. https://doi.org/10.1007/s00120-011-2644-1
doi: 10.1007/s00120-011-2644-1
Doroshyenko O, Jetter A, Odenthal KP et al (2005) Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet 44:701–720
doi: 10.2165/00003088-200544070-00003
Drake MJ, Apostolidis A, Emmanuel A et al (2017) Neurologic urinary and feacal incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A (Hrsg) Incontinence 6th International Consultation on Incontinence, Tokyo, S 1121–1128
Drake MJ, Chapple C, Esen AA et al (2016) Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4‑week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE). Eur Urol 70:136–145
doi: 10.1016/j.eururo.2016.02.030
Drake MJ, Nitti VW, Ginsberg D et al (2017) Comparative assessment of the efficacy of onabotulinumtoxin A and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis. BJU Int 120:611–622
doi: 10.1111/bju.13945
Drutz HP, Appell RA, Gleason D et al (1999) Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J 10:283–289
doi: 10.1007/s001929970003
Dykstra DD, Sidi AA, Scott AB et al (1988) Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 139:919–922
doi: 10.1016/S0022-5347(17)42717-0
Ellsworth PI, Borgstein NG, Nijman RJM et al (2005) Use of tolterodine in children with neurogenic detrusor overactivity: relationship between dose and urodynamic response. J Urol 174:1647–1651
doi: 10.1097/01.ju.0000176622.81796.89
Ethans KD, Nance PW, Bard RJ et al (2004) Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. J Spinal Cord Med 27:214–218
doi: 10.1080/10790268.2004.11753751
European Medical Agency (2009) Zusammenfassung der Merkmale des Arzneimittels – Emselex
Frohme C, Varga Z, Olbert P et al (2010) Wirkung von Botulinumtoxin A in der ein- und mehrmaligen Behandlung der überaktiven Blase. Eine prospektive Analyse. Urologe 49:639–644
doi: 10.1007/s00120-009-2208-9
Geyer J, Gavrilova O, Petzinger E (2009) The role of P‑glycoprotein in limiting brain penetration of the peripherally acting anticholinergic overactive bladder drug trospium chloride. Drug Metab Dispos 37:1371–1374
doi: 10.1124/dmd.109.027144
Gilja I, Radej M, Kovacic M et al (1984) Conservative treatment of female stress incontinence with imipramine. J Urol 132:909–911
doi: 10.1016/S0022-5347(17)49941-1
Ginsberg D, Gousse A, Keppenne V et al (2012) Phase 3 efficacy and tolerability study of onabotulinumtoxin A for urinary incontinence from neurogenic detrusor overactivity. J Urol 187:2131–2139
doi: 10.1016/j.juro.2012.01.125
Goepel M, Steinwachs KC (2007) Wie beeinflussen Medikamente zur Therapie der Harninkontinenz die Gehirnfunktion beim älteren Menschen? Urologe 46:387–392
doi: 10.1007/s00120-007-1326-5
Goessaert ASOM, Everaert KCMM (2012) Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury and multiple sclerosis. Expert Rev Neurother 12:763–775
doi: 10.1586/ern.12.61
Goessl C, Sauter T, Michael T et al (2000) Efficacy and tolerability of tolterodine in children with detrusor hperreflexia. Urology 55:414–418
doi: 10.1016/S0090-4295(99)00477-X
Hampel C, Thüroff JW (2012) Pharmakologie des Harntraktes. In: Schultz-Lampel D, Goepel M, Haferkamp A (Hrsg) Urodynamik. Springer, Berlin, Heidelberg, S 18–36
Hebert KP, Klarskov P, Bagi P et al (2020) Long term continuation with repeated botulinum toxin A injections in people with neurogenic detrusor overactivity after spinal cord injury. Spinal Cord 58:675–681
doi: 10.1038/s41393-019-0411-0
Horstmann M, Schaefer T, Aguilar Y et al (2006) Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn 25:441–445
doi: 10.1002/nau.20289
Hunsballe JM, Djurhuus JC (2001) Clinical options for imipramine in the management of urinary incontinence. Urol Res 29:118–125
doi: 10.1007/s002400100175
Ikpeze T, Mesfin A (2017) Spinal cord injury in the geriatric population: risk factors, treatment options, and long-term management. Geriatr Orthop Surg Rehabil 8:115–118
doi: 10.1177/2151458517696680
Jost WH (2013) Urological problems in Parkinson’s disease: clinical aspects. J Neural Transm 120:587–591
doi: 10.1007/s00702-012-0914-8
Jung SY, Fraser MO, Ozawa H et al (1999) Urethral afferent nerve activity affects the micturition reflex: implication for the relationship between stress incontinence and detrusor instability. J Urol 162:204–212
doi: 10.1097/00005392-199907000-00069
Kaga K, Yamanishi T, Kaga M et al (2020) Urodynamic efficacy of fesoterodine for the treatment of neurogenic detrusor overactivity and/or low compliance bladder. Int J Urol 27:899–904
doi: 10.1111/iju.14319
Kay G, Crook T, Rekeda L et al (2006) Differential effects of the antimuscarinc agents darifenacin and oxybutynin ER in memory in older subjects. Eur Urol 50:317–326
doi: 10.1016/j.eururo.2006.03.057
Kay GG, Ebinger U (2008) Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract 62:1792–1800
doi: 10.1111/j.1742-1241.2008.01849.x
Kelleher C, Hakimi Z, Zur R et al (2018) Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol 74:324–333
doi: 10.1016/j.eururo.2018.03.020
Kennelly MJ, Devoe WB (2008) Overactive bladder: pharmacologic treatments in the neurogenic population. Rev Urol 10:182–191
Kieswetter H (1979) Medikamentöse Behandlung. In: Urologie bei Rückenmarkverletzten. Springer, Berlin, Heidelberg, S 54–71
doi: 10.1007/978-3-642-67146-3_7
Kim YJ, Tae BS, Bae JH (2020) Cognitive function and urologic medications for lower urinary tract symptoms. Int Neurourol J 24:231–240
doi: 10.5213/inj.2040082.041
Kim YT, Yoshimura N, Masuda H et al (2005) Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. Urology 65:238–242
doi: 10.1016/j.urology.2004.11.021
Konstantinidis C, Samarinas M, Kratiras Z et al (2020) Efficacy of fesoterodine fumurate in neurogenic detrusor overactivity due to spinal cord lesions and multiple sclerosis (MS)—a prospective study. ICS Online
Kosilov K, Loparev SA, Ivanovaskaya MA et al (2014) Comparative effectiveness of combined low- and standard-dose trospium and solifenacin for moderate averactive bladder symptoms in elderly men and women. Urol Int 93:470–473
doi: 10.1159/000363658
Kranz J, Petzinger E, Geyer J (2013) Brain penetration of the OAB drug trospium chloride is not increased in aged mice. World J Urol 31:219–224
doi: 10.1007/s00345-011-0803-z
Krebs J, Pannek J (2013) Effects of solifenacin in patients with neurogenic detrusor overactivity as a result of spinal cord injury. Spinal Cord 51:306–309
doi: 10.1038/sc.2012.164
Krhut J, Borovicka V, Bílková K (2018) Efficacy and safety of mirabegron for the tratment of neurogenic detrusor overactivity—prospective, randomized, double-blind, placebo-controlled study. Neurourol Urodyn 37:2226–2233
doi: 10.1002/nau.23566
Kroll P (2017) Pharmacotherapy for pediatric neurogenic bladder. Pediatr Drugs 19:463–478
doi: 10.1007/s40272-017-0249-x
Kutzenberger J, Angermund A, Domurath B et al (2022) Medikamentöse Therapie der neurogenen Dysfunktion des unteren Harntraltes (NLUTD) S2k Leitlinie AWMF-Register-Nr. 043-053. https://www.awmf.org/leitlinien/detail/ll/043-053.html . Zugegriffen: 30. Juni 2022
Leitner L, Guggenbühl-Roy S, Knüpfer SC et al (2016) More than 15 years of experience with intradetrusor onabotulinumtoxin A injections for treating refractory neurogenic detrusor overactivity: lessons to be learned. Eur Urol 70:522–528
doi: 10.1016/j.eururo.2016.03.052
Leyson JFJ, Martin BF, Sporer A (1980) Baclofen in the treatment of detrusor sphincter dyssynergia in spinal cord injury patients. J Urol 124:82–84
doi: 10.1016/S0022-5347(17)55307-0
Lin HH, Sheu BC, Lo MC et al (1999) Comparison of treatment outcomes for imipramine for female genuine stress incontinence. Br J Obstet Gynecol 106:1089–1092
doi: 10.1111/j.1471-0528.1999.tb08119.x
Madersbacher H (1990) The various types of neurogenic bladder dysfunction: an update of current therapeutic concepts. Paraplegia 28:217–229
Madersbacher H, Mürtz G, Stöhrer M (2013) Neurogenic detrusor overactivity in adults: a review on efficacy, tolerabilty and safety of oral antimuscarinics. Spinal Cord 51:432–441
doi: 10.1038/sc.2013.19
Madersbacher H, Stöhrer M, Richter R et al (1995) Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. Br J Urol 75:452–456
doi: 10.1111/j.1464-410X.1995.tb07264.x
Madhuvrata P, Cody JD, Ellis G et al (2012) Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 1:CD5429
Madhuvrata P, Singh M, Hasafa Z et al (2012) Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur Urol 62:816–830
doi: 10.1016/j.eururo.2012.02.036
Malhotra B, El-Tahtawy A, Wang EQ et al (2012) Dose-escalating study of the pharmacokinetics and tolerability of fesoterodin in children with overactive bladder. J Pediatr Urol 8:336–342
doi: 10.1016/j.jpurol.2012.02.008
Medhi B, Mittal N, Bansal D et al (2013) Comparison of tolterodine with standard treatment in pediatric patients with non-neurogenic dysfunctional voiding/over active bladder: a systemativ review. Indian J Physiol Pharmacol 57:343–353
Menarini M, Del Popolo G, Di Benedetto P et al (2006) Trospium chloride in patients with neurogenic detrusor overactivty: Is dose titration of benefit to the patients? Int J Clin Pharmacol Ther 44:623–632
doi: 10.5414/CPP44623
Moon KH, Park CH, Jung HC et al (2015) A 12-week, open label, multi-center study to evaluate the clinical efficacy and safety of silodosin on voiding dysfunction in patients with neurogenic bladder. Low Urin Tract Symptoms 7:27–31
doi: 10.1111/luts.12044
Muderrisoglu AE, Becher KF, Madersbacher S et al (2019) Cognitive and mood side effects of lower urinary tract medication. Expert Opin Drug Saf 18:915–923
doi: 10.1080/14740338.2019.1652269
Murakami S, Yoshida M, Iwashita H et al (2003) Pharmacological effects of KRP-197 on the human isolated urinary bladder. Urol Int 71:290–298
doi: 10.1159/000072681
Nanninga JB, Frost F, Penn R (1989) Effect of intrathecal baclofen on bladder and sphincter function. J Urol 142:101–105
doi: 10.1016/S0022-5347(17)38673-1
NCT (2022) A study to find out how fesoterodine works in children aged 6 to 17 years with bladder overactivity caused by a neurological condition. https://clinicaltrials.gov/ct2/show/NCT01557244 . Zugegriffen: 30. Juli 2022
Nijman R, Tekgul S, Chase J et al (2017) Diagnosis and management of urinary incontience in childhood. In: Abrams P, Cardozo L, Wagg A, Wein A (Hrsg) Incontinence 6th International Consultation on Incontinence, Tokyo, S 1010–1016
Nilvebrant L, Hallén B, Larsson G (1997) Tolterodine—a new bladder selective muscarinic receptor antagonist: Preclinical pharmacological and clinical data. Proc Natl Sci Counc Repub China B 60:1129–1136
O’Leary M, Erickson JR, Smith CP et al (2003) Effect of controlled-relase oxybutynin on neurogenic bladder function in spinal cord injury. J Spinal Cord Med 26:159–162
doi: 10.1080/10790268.2003.11753678
Oelke M, Becher K, Castro-Diaz D et al (2015) Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014). Age Ageing 44:745–755
doi: 10.1093/ageing/afv077
Pannek J, Janek S, Sommerer F et al (2009) Expression of purinergic P2X2-receptors in neurogenic bladder dysfunction due to spinal cord injury: a preliminary immunohistochemical study. Spinal Cord 47:561–564
doi: 10.1038/sc.2008.165
Petit H, Wiart L, Gaujard E et al (1998) Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease. Spinal Cord 36:91–94
doi: 10.1038/sj.sc.3100517
Petri H (2015) Das Interaktionspotential der urologischen Spasmolytika. CYP450-Wechselwirkungen. Dtsch Arztebl 112:32
Peyronnet B, Castel-Lacanal E, Roumiguie M (2017) Intradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin A (Dysport®) 750 U in the management of neurogenic detrusor overactivity: a case control study. Neurourol Urodyn 36:734–739
doi: 10.1002/nau.23009
Polishchuk V, Domurath B (2015) Ist die Effektivität der intravesikalen Injektion von Botox® bei querschnittgelähmten Patienten eine Dosisfrage? Ein Vergleich von 200 AE, 300 AE und 400 AE. 28. Jahretagung DMGP, Kassel. Abstractband, S 15
Reddy PP, Borgstein NG, Nijman RJM et al (2008) Long-term efficacy and safety of tolterodine in children with neurogenic detrusor overactivity. J Pediatr Urol 4:428–433
doi: 10.1016/j.jpurol.2008.05.003
Rivas DA, Chancellor MB, Hill K et al (1993) Neurological manifestations of baclofen withdrawal. J Urol 150:1903–1905
doi: 10.1016/S0022-5347(17)35930-X
Robinson DS, Barker E (1976) Tricyclic antidepressant cardiotoxicity. JAMA 236:2089–2090
doi: 10.1001/jama.1976.03270190045029
Roy CW, Wakefield IR (1986) Baclofen pseudopsychosis: case report. Paraplegia 24:318–321
Schneider MP, Tornic J, Sykora R et al (2019) Alpha-blockers for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: a systematic review and meta-analysis. A report from the Neuro-Urology Promotion Comittee of the International Continence Society (ICS). Neurourol Urodyn 38:1482–1491
doi: 10.1002/nau.24039
Schröder A, Albrecht U, Schnitker J et al (2016) Efficacy, safety, and tolerability of intravesically administered 0.1 % oxybutynin hydrochloride solution in adult patients with neurogenic bladder: a randomized, prospective, controlled multi-center trial. Neurourol Urodyn 35:582–588
doi: 10.1002/nau.22755
Schulte-Baukloh H, Bauer R, Jost W et al (2019) Botulinumtoxin bei Blasenfunktionsstörungen. Fortschr Neurol Psychiatr 87:23–30
doi: 10.1055/a-0599-0697
Schurch B, Hauri D, Rodic B et al (1996) Botulinum—a toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 155:1023–1029
doi: 10.1016/S0022-5347(01)66376-6
Singh IK, Bajpaj M (2014) A clinical and urodynamic study on the effects of oral tolterodine on serial alterations in neurogenic detrusor overactivity vis-à-vis oral oxybutynin in children (existing oxybutynin users). J Progr Paediatr Urol 17:84–88
Soebadi MA, Hakim L, Van Der Aa F et al (2019) Real-life data on mirabegron in neurogenic bladder dysfunction. Urol Int 16:1–7
Staskin D, Kay G, Tannenbaum C et al (2010) Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract 64:1294–1300
doi: 10.1111/j.1742-1241.2010.02433.x
Staskin D, Kay G, Tannenbaum C et al (2010) Trospium chloride is undetectable in the older human central nervous system. J Am Geriatr Soc 58:1618–1619
doi: 10.1111/j.1532-5415.2010.02988.x
Statistisches Bundesamt (2022) Bevölkerung – Ältere Menschen – Die Bevölkerungsgruppe der älteren Menschen ab 65 Jahren. http://www.destatis.de . Zugegriffen: 30. Juli 2022
Stein R, Bogaert G, Dogan HS et al (2020) EAU/ESPU guidelines on the mangement of neurogenic bladder in children and adolescent part I diagnostics and conservative treatment. Neurourol Urodyn 39:45–57
doi: 10.1002/nau.24211
Stöhrer M, Madersbacher H, Richter R et al (1999) Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia—a double-blind, placebo-controlled clinical trial. Spinal Cord 37:196–200
doi: 10.1038/sj.sc.3100750
Stöhrer M, Mürtz G, Kramer G (2013) Efficacy and tolerability of propiverine hydrochloride extended-release compared with immediate-release in patients with neurogenic detrusor overactivity. Spinal Cord 51:419–423
doi: 10.1038/sc.2012.174
Stöhrer M, Mürtz G, Kramer G et al (2007) Propiverine compared to oxybutynin in neurogenic detrusor overactivity—results of a randomized, double-blind, multicenter clinical study. Eur Urol 51:235–242
doi: 10.1016/j.eururo.2006.03.016
Stothers L, Tsang B, Nigro M et al (2016) An integrative review of standardized clinical evaluation tool utilization in anticholinergic drug trials for neurogenic lower urinary tract dysfunction. Spinal Cord 54:1114–1120
doi: 10.1038/sc.2016.63
Talalla A, Grundy D, Macdonell R (1990) The effect of intrathecal baclofen on the lower urinary tract in paraplegia. Paraplegia 28:420–427
Food and Drug Administration (2011) Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103000s5232lbl.pdf . Zugegriffen: 31. Mai 2022
Van Rey F, Heesakkers J (2011) Solifenacin in multiple sclerosis patients with overactive bladder: a prospective study. Adv Urol 2011:834753
Visco AG, Brubaker L, Richter HE et al (2012) Anticholinergic therapy vs. onabotulinumtoxin A for urgency urinary incontinence. N Engl J Med 367:1803–1813
doi: 10.1056/NEJMoa1208872
Visco AG, Zyczynski H, Brubaker L et al (2016) Cost-effectiveness analysis of anticholinergics versus botox for urgency urinary incontinence: results from the anticholinergic versus botox comparison randomized trial. Female Pelvic Med Reconstr Surg 22:311–316
doi: 10.1097/SPV.0000000000000277
Wagg A, Cardozo L, Nitti VW et al (2014) The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients. Age Ageing 43:666–675
doi: 10.1093/ageing/afu017
Wolfesberger J, Falkensammer CE, Madersbacher S (2017) Blasenspeicher- und Entleerungsstörungen. Urologe 56:456–464
doi: 10.1007/s00120-017-0339-y
Wöllner J, Pannek J (2016) Initial experience with the treatment of neurogenic detrusor overactivity with a new β‑3 agonist (mirabegron) in patients with spinal cord injury. Spinal Cord 54:78–82
doi: 10.1038/sc.2015.195
Wyndaele JJ, Van Dromme SA (2002) Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord 40:599–600
doi: 10.1038/sj.sc.3101318
Yamaguchi O, Kakizaki H, Homma Y et al (2015) Safety and efficacy of mirabegron as „add-on“therapy in patients with overactive bladder treated with solifenacin: a post-marketing,open-label study in Japan (MILAI study). BJU Int 116:612–622
doi: 10.1111/bju.13068
Yildiz N, Akkoc Y, Erhan B et al (2014) Neurogenic bladder in patients with traumatic spinal cord injury: treatment and follow-up. Spinal Cord 52:462–467
doi: 10.1038/sc.2014.41
Zesiewicz TA, Evatt M, Vaughan CP et al (2015) Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson’s disease. Parkonsonism Relat Disord 21:514–520
doi: 10.1016/j.parkreldis.2015.02.025